Lecanemab trial in AD brings hope but requires greater clarity

Affiliations

¹ Clinical and Translational Neuroscience Section, Laboratory of Behavioral Neuroscience, National Institute on Aging, Baltimore, MD, USA. thambisettym@mail.nih.gov.
² Division of Psychiatry, University College London, London, UK.

Comment

Madhav Thambisetty et al. Nat Rev Neurol. 2023 Mar.

. 2023 Mar;19(3):132-133.

doi: 10.1038/s41582-022-00768-w.

¹ Clinical and Translational Neuroscience Section, Laboratory of Behavioral Neuroscience, National Institute on Aging, Baltimore, MD, USA. thambisettym@mail.nih.gov.
² Division of Psychiatry, University College London, London, UK.

No abstract available

Comment on

Lecanemab in Early Alzheimer's Disease.
van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T. van Dyck CH, et al. N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29. N Engl J Med. 2023. PMID: 36449413 Clinical Trial.

1. van Dyck, C. H. et al. Lecanemab in early Alzheimer’s disease. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2212948 (2022). - DOI - PubMed
1. Ackley, S. F. et al. Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis. BMJ 372, n156 (2021). - DOI - PubMed - PMC
1. Gleason, A., Ayton, S. & Bush, A. I. Unblinded by the light: amyloid-related imaging abnormalities in Alzheimer’s clinical trials. Eur. J. Neurol. 28, e1 (2021). - DOI - PubMed
1. Center for Drug Evaluation and Research. Aduhelm (aducanumab) FDA statistical review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000S... (2021).
1. Andrews, J. S. et al. Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer’s disease clinical trials. Alzheimers Dement. (N.Y.) 5, 354–363 (2019). - DOI - PubMed